Macleods Pharmaceuticals Limited IPO

Its may experience a shortfall in the supply of the company's raw materials or an increase in their prices, or of other input costs.

Its could experience a material slowdown or shutdown in its manufacturing or R&D operations.

Manufacturing activities may subject its to regulatory action, litigation or other liabilities.

Failure to meet various quality standards and good manufacturing practices may result in increased product liabilities.

The company is subject to extensive government regulation and may fail to obtain, maintain or renew statutory and regulatory licenses, permits and approvals required to operate its business both in India and abroad.

Its derive a significant portion of its revenue from operations from a limited number of markets.

The Company, some of its Subsidiaries and certain of its Promoters and Directors are involved in certain legal proceedings.

The Pro Forma Consolidated Financial Information included in this Draft Red Herring Prospectus to reflect the Demerger is not indicative of its expected results or operations in the future periods or its future financial position or a substitute for its past results.

Its may be unable to obtain and maintain the intellectual property rights for its brands, or otherwise protect its proprietary information.

The company depend on certain therapeutic areas for a significant portion of its total revenue.